Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks

NCT01060878 is registered in ClinicalTrials.gov with Phytopharm as lead sponsor.

NCT NCT01060878
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01060878 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of PYM50028 in Subjects With Early-stage Parkinson's Disease Administered Once Daily for 28 Weeks
Lead sponsor
Phytopharm
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
December 31, 2012
Enrollment
425 (actual)
Sites
111

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease